View in EDS

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

Saved in:
Bibliographic Details
Title: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Authors: Diamant, Michaela, Van Gaal, Luc, Stranks, Stephen, Northrup, Justin, Dachuang Cao, Taylor, Kristin, Trautmann, Michael
Source: Lancet. 6/26/2010, Vol. 375 Issue 9733, p2234-2243. 10p. 1 Diagram, 4 Charts, 5 Graphs.
Subjects: Randomized controlled trials, Insulin therapy, Glucose, Glycosylated hemoglobin, Type 2 diabetes, Hypoglycemia, Weight loss
Abstract: The article offers information on an open-label randomized study which compared the efficacy of exenatide with insulin glargine titrated to glucose targets in lowering hemoglobin A1c. The study subjects, which involved adults with type 2 diabetes who had suboptimum glycaemic control, were randomly assigned to add exenatide or insulin glargine to their blood-glucose lowering regimens. Presented in details are the findings of the study. It concludes that exenatide is ideal for patients whose risk for hypoglycemia, weight loss and convenience are particular concerns.
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:The article offers information on an open-label randomized study which compared the efficacy of exenatide with insulin glargine titrated to glucose targets in lowering hemoglobin A1c. The study subjects, which involved adults with type 2 diabetes who had suboptimum glycaemic control, were randomly assigned to add exenatide or insulin glargine to their blood-glucose lowering regimens. Presented in details are the findings of the study. It concludes that exenatide is ideal for patients whose risk for hypoglycemia, weight loss and convenience are particular concerns.
ISSN:01406736
DOI:10.1016/S0140-6736(10)60406-0